Glucose-Responsiveness of Pancreatic β-Like (GRP β-L) Cells Generated from Human Pluripotent Stem Cells.
The International Diabetic Federation estimated that 415 million adults currently have diabetes and 318 million adults had impaired glucose tolerance, putting them at high risk of developing diabetes in the future. In Type 1 Diabetes (T1D), the β cells are lost because of autoimmune reactions. Although islet transplantation has been a promising therapy for T1D, it is greatly limited by pancreatic donors. Here, we describe a protocol to generate glucose- responsive pancreatic β-like (GRPβ-L) cells from human-induced pluripotent stem (iPS) cells. We recapitulate in vivo pancreas development by in vitro induction of differentiating human (iPS) cells with stage-specific signaling molecules and proteins. Inhibition of Tyrosine Kinase receptor AXL, TGF-β, and Notch signaling pathways in the final stage of the five-stage protocol could efficiently generate GRPβ-L from the endocrine progenitor. Differentiation of human iPS cells through the protocol could result in functional GRPβ-L cells, which could be used in pharmaceutical and β cell biology studies. © 2018 by John Wiley & Sons, Inc.
['Rajaei|Bahareh|B|', 'Massumi|Mohammad|M|', 'Wheeler|Michael|M|']
D018929:Cell Culture Techniques D002454:Cell Differentiation D019070:Cell Lineage D003922:Diabetes Mellitus, Type 1 D005947:Glucose D006801:Humans D057026:Induced Pluripotent Stem Cells D050417:Insulin-Secreting Cells D011518:Proto-Oncogene Proteins D020794:Receptor Protein-Tyrosine Kinases D051880:Receptors, Notch D015398:Signal Transduction D016212:Transforming Growth Factor beta
embryonic stem (ES) cell induced pluripotent stem (iPS) cell insulin protocol to generate beta cells β-like cells